

Ref. No. JPL/CS/1797/2022

To
The BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Date: 01st July, 2022Reg.: **Regulation 34 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015.**Sub.: **Annual Report 2021-22.**

Dear Sir,

Kindly find attached a soft copy of the Annual Report of the Company, pertaining to financial year 2021-22, inter-alia containing followings:

1. Notice convening 37th Annual General Meeting, which will be held on Friday, 29th July, 2022 at 3.30 p.m. through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). The notice also contain the instructions for e-voting and explanatory statement;
2. Audited financial statements for the financial year 2021-22 in accordance to IND-AS, with significant Accounting Policies and notes thereto;
3. Cash flow statements in accordance to IND-AS;
4. Directors' report thereon with annexures;
5. Management discussion and analysis report, as a part of directors' report;
6. Auditors' report with unmodified opinion alongwith with annexures and
7. Report on Corporate Governance.


The Annual Report is being sent through electronic mode to those Members whose e-mail addresses are registered with the Company/Registrars and Transfer Agent/Depositories. This is in accordance to the Ministry of Corporate Affairs's Circulars No. 02/2022 dated 05th May, 2022 and the Securities and Exchange Board of India's Circular no. SEBI/HO/CFD/CMD2/CIR/P/2022/62 dated 13th May, 2022.

A copy of Annual Report is also available on the website of the Company. viz. www.jenburkt.com.

Kindly take on record the above.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Limited


Ashish R. Shah
Company Secretary and Compliance Officer

Encl.: As Stated Above.

 Science hai toh Hope hai  Hope hai toh Health hai  Health hai toh Happiness hai 




Delivering Excellence in Life Sciences

2022 Annual Report

Looking back, moving forward




With a legacy of innovation and quality, today Jenburkt generates over 11 million prescriptions globally each year, and reaches 400,000 pharmacies.



In 2021, we proudly launched JENBURKT WELLNESS, where we aim to build a comprehensive portfolio of superior consumer wellness brands that blend the best of science and nature towards better physical and mental health. We combine our unique understanding of consumer's health concerns with cutting-edge Research & Development, unparalleled Quality Assurance, superior Manufacturing, and an unrelenting pursuit of excellence to deliver transformative solutions that raise the standard of healthcare.





Thoughtful Formulation :

Our Advisory Panel together with the Product Development team formulates unique, efficacious products for your wellness.

Complete Compliance:

We use the highest quality ingredients in the appropriate doses, check ease of administration and cost to the consumer while developing products.

Rigorous Evidence:


Ongoing research of the latest trends and cutting edge technology ensures that our products deliver what they promise.

Clean Conscience:

Sustainability, safety and quality assurance are key factors in our product development.

Blending the best of science and nature in the pursuit of exceptional health.

Zixa Strong is a high performance dual-action pain relief range by Jenburkt Wellness. It harnesses unique FlashMicelle Oil-in-Water technology to deliver fast-acting and long-lasting pain relief from sprains, strains, muscle & back pain as well as joint stiffness. Read on about Zixa's launch on subsequent pages.



Introducing
ZIXA
STRONG

by  **JENBURKT**
wellness

#RiseAgain
from pain with
our impossible
union of Oil &
Water

Discover the power of
our unique oil-in-water
FlashMicelle® technology
for instant pain relief

**Pain Relief Spray | Pain Relief Roll-On |
Pain Relief Gel**



Introducing Zixa Strong

Instant Relief from Intense Muscular & Joint Pain

On April 2nd, 2022 - Jenburkt Wellness, the premium consumer-wellness division from the house of publicly listed organization Jenburkt Pharmaceuticals Ltd, announced the launch of Zixa Strong, a high-performing pain-relief range that delivers fast-acting and long-lasting relief from muscle and joint pains. Created using an innovative, scientifically advanced oil-in-water FlashMicelle® technology, Zixa Strong promises to create a revolution in the pain relief category with its non-greasy, quick-absorption mechanism and unique formula for immediate pain relief.

ZIXA[®] STRONG



Oil-in-Water
FlashMicelle®
Technology



Dual Action
Composition



Strongest All-Natural Pain
Relief Formulation



Non Greasy



Lightning
Fast
Absorption



Paraben Free



No Artificial Color



No Artificial
Fragrance

The Chairman and Managing Director of Jenburkt Pharmaceuticals Limited, Ashish Uttam Bhuta, also added, ***“Every fifth person is likely to be suffering from some kind of pain, according to a study by the World Health Organization's Global Burden of Disease. With a long experience and expertise in pain management, at Jenburkt Wellness, we were inspired to pioneer a scientifically advanced, natural and skin-friendly pain relief range powered by FlashMicelle® Technology. Zixa Strong is our very first digital & first over-the-counter (OTC) brand, and we are privileged to create highly-effective powerful products that can relieve pain. We plan to add multiple products to the Zixa range over the course of this year.”***

Zixa
Strong
Spray

Zixa
Strong
Gel


Zixa
Strong Roll On






Zixa Strong was launched with much fanfare on social media.

Zixa Strong - a digital-first pain relief brand was launched with a hard-hitting and impactful Brand Film on Youtube titled "The Impossible Union of Oil & Water" that has garnered over 3,50,000 views and overwhelmingly positive feedback. Zixa Strong is active on social media channels Instagram and Facebook as well, and enjoys highly engaged communities on all platforms.



Watch the Zixa brand film on Youtube



Exploring maharashtra in my way 2 months ago
Congratulations for grand opening and best wishes.

👍 2 🗨️ ❤️ REPLY

View reply from Zixa Strong



Shrikant Sreenivasan 2 months ago
This is just too incredible! Everything in this video is next level. Great job everyone!

👍 2 🗨️ ❤️ REPLY



Shashi Sharma 2 months ago
Hearty Congratulations for a grand opening


👍 1 🗨️ ❤️ REPLY

Zixa Strong | A D2C Pain Relief Brand by Jenburkt Wellness




Customers across India can shop the Zixa Strong Pain Relief Range directly on www.zixa.co.

Zixa Website:
<https://zixa.co>





Our products are also available on Amazon!

**Zixa Products on
amazon**



#RiseAgainWithZixaStrong

"As a part of our product promotion of Zixa Strong we would run a nationwide #RiseAgainWithZixa campaign to celebrate and showcase those individuals who have risen above challenging and painful hardships and accomplished unbelievable achievements. These stories keep inspiring the ordinary to achieve the extraordinary ~ as pain is part of the process ~ all that we need to do is Rise Again," said. **Ashish Uttam Bhuta, Chairman and Managing Director** – Jenburkt Pharmaceuticals Limited.



Zixa Strong was launched with much fanfare on social media.

Our ZIXA STRONG brand launch film and product range was the talk of the town **TRENDING AT #1 ACROSS INDIA ON TWITTER** on the day of the launch.

Top mention earned 613 engagements

 **Tandrani Chandra**
@ChandraTandrani · Apr 4

This medicine is really very good and it has no side effects
[#RiseAgainWithZixa](#) [zixa.co](#)
[@zixapainrelief](#)
[pic.twitter.com/ypsWKhFEuk](#)




Experience the future of pain relief.

- ⚡ Rapid Relief From Pains & Strains
- ⚡ Long Lasting Pain Relief
- ⚡ Non-Greasy & Skin-Friendly
- ⚡ Powerful Mix of Hot & Cold Therapy
- ⚡ Strong Natural Composition

Powered by FLASHMICELLE Technology

232 134

You Retweeted

 **Lubz** @LubzCreation · Apr 4


This really wonderful for back pain , knees pain . You should must have this in your home.
[#RiseAgainWithZixa](#) [@zixapainrelief](#)

You Retweeted

 **BARKHA** @BarkhaSeth_8 · Apr 4

Strong, layered ad film with hair-raising visuals in this amazing digital ad film by [@zixapainrelief](#). [#RiseAgainWithZixa](#)

You Retweeted

 **Kareena Kapoor Khan** @kareenasart · Apr 4

One of the fast acting relief pain spray. You should must have this at home for knee pain , back pain and more.
[#RiseAgainWithZixa](#) [@zixapainrelief](#)



Experience the future of pain relief.

- ⚡ Rapid Relief From Pains & Strains
- ⚡ Long Lasting Pain Relief
- ⚡ Non-Greasy & Skin-Friendly
- ⚡ Powerful Mix of Hot & Cold Therapy
- ⚡ Strong Natural Composition

Powered by FLASHMICELLE Technology

You Retweeted

 **Legal drugdealer** @Legal_dealer · Apr 4


This is very beneficial because if you are going through any kind of knee pain or any kind of pain then this is going to be very beneficial and good for you
[#RiseAgainWithZixa](#) [@zixapainrelief](#)




Experience the future of pain relief.

- ⚡ Rapid Relief From Pains & Strains
- ⚡ Long Lasting Pain Relief
- ⚡ Non-Greasy & Skin-Friendly
- ⚡ Powerful Mix of Hot & Cold Therapy
- ⚡ Strong Natural Composition

Powered by FLASHMICELLE Technology


 **be_that_diva**


This Ad gave me goosebumps.
Incredible video [@zixapainrelief](#)




WATCH VIDEO HERE

[INSTAGRAM.COM](#)


 **surbhi.dhall** Big thanks




So excited to finally have found an amazing pain relief coz pain goes beyond the physical. Check out this powerful ad film by [@zixapainrelief](#). A must watch

 **meghachadha92**

Not just the future of pain relief, this ad is the future of advertising in the pain relief segment. So well done [@zixapainrelief](#) Excellent!




zixapainrelief

 **surbhi.dhall**

Pain is a part of the process - such a poignant, insightful line. Watch this hard-hitting visual-musical narrative for the launch of [@zixapainrelief](#)

[ZIXA](#)



zixapainrelief

Founders

Board of Directors

Company Secretary

Auditors

Bankers

Registered Office

Plant

Research & Development Centre

Registrar & Transfer Agents

Index

Notice



Notice

R. Bhavsar, Cost Accountants Firm (Registration No. 102167), appointed by the Board of Directors of the Company to conduct the audit of the Cost Records of the Company, amounting to ₹ 2,15,000/- (Rupees Two Lacs Fifteen Thousand only) be and is hereby ratified and confirmed."

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorized to do all such acts and take appropriate steps as may be necessary and proper to give effect to this resolution."

6. To consider and if thought fit, to pass the following resolution, as a Special Resolution:

"RESOLVED THAT in supersession of all such resolution passed earlier, in this regard, and pursuant to provisions of Section 94 and other applicable provisions of the Companies Act, 2013 ("the Act") and applicable Rules of the Companies (Management and Administration) Rules 2014, or any re-enactments or modifications thereof, approval of the Members of the Company be and is hereby accorded to the Company to keep the registers as mentioned under section 88 of the Act and the copies of the Annual Return under section 92 of the Act, together with the copies of documents as may be required, under any prevalent law, at the registered office of the Company and / or at the office of Bigshare Services Pvt. Ltd., the Registrar and Transfer Agent of the Company, presently located at: office No. S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri East, Mumbai, Maharashtra-400093, India and/or at such other office or place of the Registrar and Transfer Agent of the Company is situated in Mumbai, from time to time.

RESOLVED FURTHER THAT the Board of Directors or any Committee thereof of the Company be and are hereby authorized to do all such things, or take actions as may be required, from time to time, for giving effect to the forgoing."

5. To consider and if thought fit, to pass the following resolution, as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 148 and all other applicable provisions of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014 including any statutory modifications or re-enactments thereof for the time being in force, the remuneration payable for the financial year ending 31st March, 2023 to M/s Jagdish





NSDL Mobile App is available on



Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:



Annexure to the Notice

EXPLANATORY STATEMENT

Pursuant to Section 102(1) of the Companies Act, 2013 (the Act), setting out all material facts relating to the Special Business mentioned at item no.5 and 6. As an additional information, the explanatory statement also contains material facts pertaining to ordinary business mentioned at item no.4 of the Notice:

For item number 4 of the Notice:

Members of the Company on 31st July, 2017 at the 32nd AGM of the Company had approved the appointment of M/s. D. R. Mehta & Associates Chartered Accountants, Mumbai (Firm Registration Number 106207W) as the Statutory Auditors of the Company for a consecutive period of five years, till the conclusion of the 37th AGM of the Company.

Pursuant to Section 139(2) of the Companies Act, 2013 (the Act), the Company can appoint an audit firm for a second term of five consecutive years. In accordance with the Act and on the recommendation of the Audit Committee and in the best interest of the Company, the Board of Directors at their meeting held on 27th May, 2022, have considered and recommended the

proposed re-appointment of M/s. D. R. Mehta & Associates, Chartered Accountants, as the Statutory Auditors of the Company for another term of five years i.e. from the conclusion of this 37th AGM till the conclusion of 42nd AGM to be held in 2027.

In terms of the provisions of the Sections 139(1), 141(2) and 141(3) of the Act, and the provisions of the Companies (Audit and Auditors) Rules, 2014, as amended from time to time, M/s. D. R. Mehta & Associates, Chartered Accountants have consented and confirmed that they are eligible and not disqualified to be reappointed as the statutory auditors of the Company. Further, they have confirmed that their re-appointment, if made, would be within the limits specified in the Act. There has been no complaint pending against the firm/partner pertaining to professional misconduct. The firm has been peer reviewed and hold valid certificate issued in this regard by the Peer Review Board of ICAI. The remuneration to be paid to M/s. D. R. Mehta & Associates, Chartered Accountants will be decided by the Board of Directors based on recommendations of Audit Committee and with mutual consultation with the Statutory Auditors.



Directors' Report

Directors' Report

Particulars	Year ended 31 st March, 2022	Year ended 31 st March, 2021
	12,398.04	
	494.87	
	9,905.82	
	2,987.09	
	757.37	
	2,229.72	
	130.02	
	2,359.74	
	48.58	
	11,279.31	



















Annexure A

FORM NO. MR-3 SECRETARIAL AUDIT REPORT FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2022

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014] UDIN: F004554D000412269

To
The Members,
JENBURKT PHARMACEUTICALS LIMITED
Nirmala Apartments, 93, Jay Prakash Road, Andheri (West), Mumbai 400 058.

Dear Sir / Madam,

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good Corporate Governance practice by **Jenburkt Pharmaceuticals Limited** (hereinafter called "**the Company**"). The Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts / statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company, the information as provided by the Company, its officers and authorized representatives during the conduct of secretarial audit in physical /electronic form, the explanations and clarifications given to us and the representations made by the concerned employees and also considering the relaxations granted by the Ministry of Corporate Affairs and the Securities and Exchange Board of India ("SEBI") due to the spread of the COVID-19 pandemic during part of the year, we hereby report that in our opinion, the Company has during the audit period covering the financial year ended on 31st March, 2022, generally complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We herewith report that maintenance of proper and updated Books, Papers, Minutes Books, filing of Forms and Returns with applicable regulatory authorities and maintaining other records including fully functional website is responsibility of management and of the Company. Our responsibility is to verify the content of the documents produced before us, make objective evaluation of the content in respect of compliance and report thereon. We have examined on test check basis, the books, papers, minute books, forms and returns filed and other records maintained by the Company and produced before us for the financial year ended 31st March, 2022, as per the provisions of:

- (i) The Companies Act, 2013 and the rules made there under;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under (to the extent applicable to the Company);
- (iv) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - (c) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client;
 - (d) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015;
 - (e) The Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 (to the extent applicable to the Company).
- (v) The Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016

We have in-principally verified systems and mechanism which is in place and followed by the Company to ensure Compliance of the following specifically applicable Laws / Orders (in addition to the above mentioned Laws (i to iv) and applicable to the Company since the company is engaged in dealing of Pharmaceutical products) and we have also relied on the representation made by the Company and its Officers in respect of systems and mechanism formed / followed by the Company for compliances of other applicable Acts, Laws and Regulations and found the satisfactory operation of the same.

- Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics (6th Amendments) Rules, 2016
- The Drug (Price Control) Order, 2013
- Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954

'ANNEXURE - A1'
UDIN: F004554D000412269

Annexure B

Name of the Related Party and Relationship	Nature of Contract	Duration	Salient Terms	Aggregate Amount

Annexure C

Report on Corporate Social Responsibility (CSR) for the Financial Year 2021-22.

1. A brief outline of the Company's CSR Policy:

The CSR Committee of the Company identifies the project to be funded under CSR, preferably in and around the local area of its registered office and plant and after careful analysis the committee recommend its proposal to the Board for their consideration and decision thereon. The Board takes final decision about sanctioning the proposal and fund to be spent as CSR, in terms of the provision of the Companies Act, 2013, the Companies (Corporate Social responsibility Policy) Rules, 2014 and the Company's policy on CSR. The Company was involved, in its own way, into social responsibilities, prior to the mandatory CSR provisions came into effect by way of statute. Your Company believe in philanthropy i.e. giving back to the society and this culture has been inculcated by its promoters viz. Bhuta family. Based on these principles a CSR policy of the Company was framed, in pursuance of the applicable provisions of the Companies Act, 2013.

2. Composition of CSR committee:

Sr. No	Name of Director	Designation	No. of Meetings in F.Y. 2021-22	
			Held	Attended

3. Kindly refer to web-link: http://www.jenburkt.com/Other_Info/20152016/Policy%20on%20CSR.pdf for the Composition of CSR committee, Company's policy on CSR and details of the CSR projects approved by the board. Kindly refer to the corporate governance section in this Annual Report for further details regarding CSR Committee and its role etc.

4. The details of impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014, if applicable: N.A.
5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any:

(Amount in ₹)

Financial Year	Amount available for set-off from preceding financial years	Amount required to be set-off for the financial year, if any

(Amount in ₹)

6. Average net profit of the Company for last three financial years for the purpose of computation of CSR:	23,47,76,211
--	--------------

(Amount in ₹)

7. (a) Prescribed CSR expenditure (two percent of the amount as in item 3 above):	46,95,524
(b) Surplus arising out of the CSR projects or programmes or activities of the previous financial years:	Nil
(c) Amount required to be set off for the financial year, if any:	45,98,751
(d) Total CSR obligation for the financial year (7a+7b-7c):	96,773

8. (a) CSR amount spent or unspent for the financial year 2021-22:

Total Amount Spent for the Financial Year. (₹)	Amount Unspent (₹)				
	Total Amount transferred to Unspent CSR Account as per section 135(6)		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5).		
	Amount	Date of transfer	Name of the Fund	Amount	Date of transfer
1,00,000	Nil	-	-	Nil	-

- (b) Details of CSR amount spent against ongoing projects for the financial year:

Sr. No	Name of the Project	Item from the list of activities in Schedule VII to the Act	Local Area (Yes/No)	Location of the project (State and District)	Project duration	Amount allocated for the project (₹)	Amount spent in the current financial Year (₹)	Amount transferred to Unspent CSR Account for the project as per Section 135(6) (₹)	Mode of Implementation - Direct (Yes/No)	Mode of Implementation - Through Implementing Agency CSR Name Registration number
1	-	-	-	-	-	-	-	-	-	-
	Total					-	-			

- (c) Details of CSR amount spent against other than ongoing projects for the financial year:

Sr. No	Name of the Project	Item from the list of activities in Schedule VII to the Act	Local Area (Yes/No)	Location of the project State District	Amount spent for the project (₹)	Mode of Implementation - Direct (Yes/No)	Mode of Implementation - Through Implementing Agency CSR Name Registration number
1.	To fund purchasing of sports equipments for imparting training/coaching of various sports at N M Bhuta College-Sihor	Training to promote rural sports, nationally recognized sports, Paralympic sports and Olympics sports	Yes	Gujarat Bhavnagar	1,00,000	Direct	NA NA
	Total				1,00,000		
	Total of 8(b) + 8(c)				1,00,000		

- (d) Amount spent in Administrative Overheads : Nil
(e) Amount spent on Impact Assessment, if applicable : Nil
(f) Total amount spent for the Financial Year (8b+8c+8d+8e): ₹ 1,00,000
(g) Excess amount for set off, if any: ₹ 3,227

(₹ in Lacs)

Sr. No	Particular	Amount (₹)

9. (a) Details of Unspent CSR amount for the preceding three financial years:

Sr. No	Preceding Financial Year	Amount transferred to Unspent CSR Account for the project as per Section 135(6) (₹)	Amount spent in the reporting Financial Year (in ₹)	Amount transferred to any fund specified under Schedule VII as per section 135(6), if any.			Amount remaining to be spent in succeeding financial years. (₹)
				Name of the Fund	Amount (in ₹)	Date of transfer	
1		Nil	Nil		Nil		Nil
	Total	Nil	Nil		Nil		Nil

(b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s):

Sr. No	Project ID	Name of the Project	Financial Year in which the project was commenced	Project duration	Total amount allocated for the project (₹)	Amount spent on the project in the reporting Financial Year (₹)	Cumulative amount spent at the end of reporting Financial Year (₹)	Status of the project - Completed / Ongoing
1								
	Total							

10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year: No such case.

11. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5): N.A. The Company has spent in excess of the required spending, as detailed above.

For Jenburkt Pharmaceuticals Ltd.

For Jenburkt Pharmaceuticals Ltd.

Sd/-

Arun R. Raskapurwala
Independent Director
(Chairman, CSR Committee)

Sd/-

Ashish U. Bhuta
Chairman and Managing Director.
(Member, CSR Committee)

Mumbai, 27th May, 2022.

Annexure D

Conservation of Energy, Technology Absorption, Foreign exchange earnings and outgo:

[Particulars pursuant to Section 134(3)(m) of the Companies Act, 2013 read with Rule (8)(3) of Companies (Accounts) Rules, 2014 and forming part of the Directors' Report, for the financial year ended on 31st March, 2022.]

(A) Conservation of energy:

i. The steps taken or impact on conservation of energy.

- a. Power factor maintained near unity at Sihor manufacturing facilities and R&D resulted curtailment of power losses.
- b. The Company has installed new VRV air conditioning system in R&D lab as this system is acknowledged for its energy saving technology.

ii. The steps taken by Company to utilise alternate source of energy.

- a. The company is using Bio-diesel in place of normal diesel for operations of Steam boilers.

iii. The capital investment on energy conservation equipments:

- a. VRV System Approx. ₹ 11.00 lacs.

(B) Technology absorption, adoption and innovation:

i. Efforts in brief made towards technology absorption.

- a. Research & Development plays a vital role in developing and adopting new technologies to enhance our operational efficiencies.
- b. The Company has developed and introduced a series of products into the market under ZIXA brand through digital portal. These products contains ingredients from natural and plant source and are useful in our day to day life.

ii. The benefits derived like product improvement, cost reduction, product development or import substitution.

Technology adoption resulted in

- a. Product yield improvement.
- b. Availability of products at affordable price.
- c. Entry into newer markets and export of quality products.

iii. The details of imported technology (imported during last 3 years)

- a. The details of technology imported : NIL
- b. The year of import : NIL
- c. Whether the technology been fully absorbed : NIL
- d. If not fully absorbed, areas where absorption has not taken place and the reasons thereof : NIL

iv. The expenditure incurred on research and development.

Capital Expenditure: ₹ Nil, Recurring Expenditure: ₹ 115.95 Lacs.

v. Foreign exchange earnings and outgo.

During the year under review, the foreign exchange earnings by the Company was ₹ 2,102.58 lac and the foreign exchange expenditure of the Company was ₹ 277.19 lac (including ₹ 0.31 lac towards dividend on equity shares).

For and on behalf of the Board of Directors

Ashish U. Bhuta
Chairman and Managing Director

Mumbai, 27th May, 2022

Annexure E

Sr. No.	Director / Key Managerial Personnel	Remuneration for the Year 2021-22 (₹ in Lacs)	Percentage increase in Remuneration in 2021-22	Ratio of remuneration to median remuneration

Mumbai, 27th May, 2022.

Corporate Governance



Corporate Governance Report

Name of the Director	Category of directorship / designation	No. of Board meetings in FY. 2021-22		Attendance at last AGM held by OAVM	No. of directorships held in another Company	No. of equity shares held as on 31 st March, 2022
		Held	Attended			



Name of director	Category of directorship	No. of Meetings in F.Y. 2021-22	
		Held	Attended

Name of director	Category of directorship	No. of Meetings in F.Y. 2021-22	
		Held	Attended

Name of director	Remuneration including salary, perquisites and all benefits (₹)	Sitting fees (₹)	Total (₹)	Present service contract

Name of director	Category of directorship	No. of Meetings in F.Y. 2021-22	
		Held	Attended

Name of director	Category of directorship	No. of Meetings in F.Y. 2021-22	
		Held	Attended

Financial Year	Venue	Date & Time	Special resolutions passed







AGM: Date and Timing

Financial calendar
(Proposed) for F.Y. 2021-22.

Cut-off date
Date of book closure
Expected date of dividend payment
Listing of equity shares on
Stock Exchange

Stock Code
Security ISIN No.
Company's Registration No.

2021-2022

Company's share price

BSE Sensex


Month

High (₹)

Low (₹)

High

Low



Details of RTA	
Share Transmission and Dematerialisation System	

Sr. No.	Category	No. of Shares held	% of shareholding

No. of Equity Shares held	No. of Shareholders	% of Shareholders	No. of Shares	% of Shareholding

Type of Shareholding	No. of Share holders	% of Share-holders	No. of Shares	% of Shareholding

Dematerialisation of equity shares and liquidity	
Plant Location	
Investor correspondence be addressed to	
Address for Correspondence	

Sr. No. Name of the policy / code and other items along with respective weblink



Certificate on Corporate Governance

Auditors' Report

Independent Auditors' Report

Sr.No.	Key Audit Matter	Auditors Response

--	--	--



Annexure-A to the Independent Auditors' Report

Annexure-B to the Independent Auditors' Report

Statute	Nature of Dues	Amount (₹ in lac)	Period	Forum where dispute is pending





Financial Statements

Balance Sheet as at 31st March, 2022

Particulars	Note	31/03/2022	31/03/2021
		995.36	
		113.94	
		-	
		30.57	
		21.17	
		796.12	
		13.28	
		3,566.00	
		37.11	
		1,130.97	
		988.77	
		-	
		1,520.68	
		503.13	
		4,399.18	
		18.97	
		27.40	
		109.70	
		22.58	
		14,294.91	
		458.94	
		11,279.31	
		48.86	
		294.25	
		85.57	
		45.11	
		581.53	
		24.71	
		686.33	
		555.52	
		201.15	
		25.93	
		7.70	
		14,294.91	

Statement of Profit & Loss for the year ended 31st March, 2022

Particulars	Note	31/03/2022	31/03/2021
		12,398.04	
		494.87	
		12,892.91	
		1,173.86	
		2,198.08	
		(228.47)	
		3,649.09	
		43.44	
		189.86	
		2,879.94	
		9,905.82	
		2,987.09	
		735.00	
		(7.21)	
		29.58	
		2,229.72	
		140.57	
		(10.55)	
		-	
		-	
		2,359.74	
		48.58	

Cash Flow Statement as on 31st March, 2022

Particulars	Note	31/03/2022	31/03/2021
		2,229.72	
		189.86	
		(3.33)	
		757.37	
		43.44	
		(437.13)	
		(3.28)	
		(0.21)	
		8.37	
		(24.45)	
		1.92	
		2,762.29	
		(230.62)	
		(104.52)	
		(1,114.01)	
		251.79	
		210.46	
		(25.49)	
		(53.73)	
		1,696.17	
		(756.07)	
		940.10	
		(305.43)	
		50.64	
		(48.44)	
		20.76	
		(12,952.19)	
		12,606.89	
		(74.26)	
		61.31	
		504.26	
		3.28	
		(133.19)	
		(34.10)	
		(468.04)	
		(51.00)	
		(553.14)	
		253.76	
		249.37	
		503.13	
		253.76	

Statement of Changes in Equity

Particulars	Reserves & Surplus			Equity Instrument through OCI	Other Income of OCI	Total
	Other Reserves	Capital Redemption Reserve	Retained Earnings			
	334.62	5.99	9,091.07			
	-	-	-			
	-	-	-			
	-	-	2,229.72			
	-	-	(468.12)			
	-	-	-			
	-	-	-			
	334.62	5.99	10,852.68			

Particulars	Reserves & Surplus			Equity Instrument through OCI	Other Income of OCI	Total
	Other Reserves	Capital Redemption Reserve	Retained Earnings			
	334.62	5.99	7,440.83			
	-	-	-			
	-	-	-			
	-	-	1,650.24			
	-	-	-			
	-	-	-			
	-	-	-			
	334.62	5.99	9,091.07			

Notes to Accounts



Significant Accounting Policies

Particular	Depreciation

Capital Work in Progress:		Amount in CWIP as on 31 st March 2022			
Projects in progress	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total

Capital Work in Progress:		Amount in CWIP as on 31 st March 2021			
Projects in progress	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total

Particular	Depreciation

Intangible Asset under Development		Amount in CWIP as on 31 st March 2022			
Projects in progress	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total

Intangible Asset under Development		Amount in CWIP as on 31 st March 2021			
Projects in progress	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total





Sales	2021-22 (₹)	2020-21 (₹)



Particulars	2021-22	2020-21
	24.71 0.28	
	90.32 0.08	
	0.28	
	0.28	

Particulars	2021-22 Amount ₹. in Lacs	2020-21 Amount ₹. in Lacs
	46.96	
	1.00	
	45.99	
	0.03	
	-	
	-	
	Training to promote rural sports, nationally recognized sports, paralympic sports and olympic sports	
	-	
	NA	

Notes forming part to Balance Sheet as at 31st March, 2022

Particulars	Factory Building	Office Building*	Godown Building	Plant & Equipment General	Plant & Equipment R&D	Furniture & Fixtures	Electrical Fixtures	Computers	Office Equipment	Vehicle	Total
At cost or deemed cost											
Accumulated depreciations and impairment											
Carrying Amount											
As at March 31, 2021	290.38	193.14	3.63	214.80	44.64	18.65	11.24	37.21	9.66	27.34	850.69
As at March 31, 2022	311.41	182.63	3.53	241.31	36.60	42.41	20.24	43.83	22.02	91.37	995.36

Particulars	Right to Use Asset			Goodwill	Intangible Asset			Capital WIP
	Land#	Building	Total		Trademark	Computer	Total	
At cost or deemed cost								
Accumulated amortisation and impairment								
Carrying Amount								
As at March 31, 2021	30.46	125.76	156.22	0.14	7.71	40.24	47.96	37.76
As at March 31, 2022	30.10	83.84	113.94	-	5.78	24.78	30.57	21.17

Particulars	As at 31 st March, 2022			As at 31 st March, 2021			Face Value
	Units	Market Value	Cost	Units	Market Value	Cost	
Investments measured at Amortised Cost							
	3,012	33.16	30.12				
		33.16	30.12				
Investments measured at Fair Value through Other Comprehensive Income							
	1,366	1.52	1.06				
	151	0.00	0.10				
	10,000	147.00	0.21				
	550	4.02	1.29				
	200	0.09	0.24				
	500	0.20	-				
	500	0.31	1.11				
	2,000	0.22	0.47				
	150	0.01	0.47				
	130	0.95	0.83				
	5	3.25	0.30				
	4,222	5.70	2.18				
	2,000	4.34	2.09				
	24	0.63	0.30				
	372	9.80	1.90				
	62	1.01	-				
	500	0.55	1.10				
	3,519	0.46	0.00				
	30,000	13.24	8.73				
		193.29	22.40				
Investments measured at Fair Value through Other Comprehensive Income							
	25,861	33.02	26.83				
	2,849	32.35	20.00				
	2,500	0.41	0.25				
	19,382	66.20	41.36				
	70,352	55.93	36.53				
	18,270	41.28	23.17				
	1,70,320	88.52	57.93				
	1,22,231	45.09	31.50				
	89,130	51.40	31.79				
	37,403	0.02	-				
	37,403	-	-				
	37,403	27.25	21.72				
	1,68,163	85.23	54.99				
	35,374	15.84	16.00				
	4,294	1.97	2.00				
	4,898	8.05	8.00				
	24,239	4.50	4.50				
	11,295	2.00	2.00				
	224	0.97	1.00				
	4,059	7.96	8.00				
	6,313	2.72	3.00				
	790	2.00	2.00				
		572.70	392.58				
		796.12	445.10				

	As at 31 st March, 2022	As at 31 st March, 2021
	13.28 13.28	
	3,540.28 25.72 3,566.00	
	(8.32)	
	7.06 (25.66) (0.63) 0.14 (10.48) (29.58) (10.55) (10.55) (48.46)	
	(45.26) 23.65 - - (40.16) (0.15) 6.53 6.94 (48.46)	
	37.11 (85.57) (48.46)	
	1,110.07 20.90 1,130.97	
	172.99 146.60 45.41 182.22 426.78 14.78 988.77	

Particulars	As at 31 st March, 2022			As at 31 st March, 2021		
	Units	Market Value	Cost	Units	Market Value	Cost
Investments measured at Fair Value through Other Comprehensive Income						
	-	-	-			
	-	-	-			
	-	-	-			
	-	-	-			
	-	-	-			
	-	-	-			

	As at 31 st March, 2022	As at 31 st March, 2021
	1,520.68	
	27.57	
	(27.57)	
	1,520.68	

	480.34	
	12.25	
	9.24	
	1.31	
	503.13	

	70.45	
	412.10	
	5.54	
	3,743.35	
	167.74	
	4,328.73	
	4,399.18	

	18.97	
	18.97	

	0.53	
	10.12	
	16.75	
	27.40	

	As at 31 st March, 2022	As at 31 st March, 2021
	30.19	
	1.04	
	12.04	
	0.29	
	10.21	
	55.33	
	0.60	
	109.70	

	-	
	-	
	-	
	(7.70)	
	-	
	6.63	
	15.94	
	14.87	

	22.58	
	(7.70)	
	14.87	

	(13.41)	
	(735.00)	
	(763.28)	
	14.87	

	1,000.00	
	458.94	
	-	
	458.94	

	As at 31 st March, 2022		As at 31 st March, 2021	
	No. of Shares	% held	No. of Shares	% held
	6,16,128	13.43		
	2,61,127	5.69		
	5,36,480	11.69		
	3,99,700	8.71		

	6,16,128	13.43		
	2,61,127	5.69		

	As at 31 March, 2022	As at 31 March, 2021
	No. of Shares	No. of Shares
	45,89,378	
	45,89,378	

	As at 31 st March, 2022	As at 31 st March, 2021
	5.99	
	5.99	
	334.62	
	334.62	
	9,091.07	
	2,229.72	
	(468.12)	
	10,852.68	
	(43.99)	
	92.93	
	47.64	
	(10.55)	
	86.02	
	11,279.31	

	468.12	
--	--------	--

	48.86	
	48.86	

	294.25	
	294.25	

	45.11	
	45.11	

	437.45	
	144.02	
	0.05	
	581.53	

Facility taken (With Interest Rate)	As at 31 st March, 2022			As at 31 st March, 2021		
	Limit	Face Value	Present Value	Limit	Face Value	Present Value

	As at 31 st March, 2022	As at 31 st March, 2021
	8.15	
	-	
	11.95	
	4.61	24.71
	69.28	
	75.05	
	413.79	
	128.22	-
	711.03	

Particulars	Outstanding for following periods from due date of payment as on 31 st March 2022					
	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total

Particulars	Outstanding for following periods from due date of payment as on 31 st March 2021					
	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total

	As at 31 st March, 2021	As at 31 st March, 2020
	-	
	-	
	70.45	
	485.08	
	555.52	

	115.22	
	85.93	
	201.15	

	25.93	
	-	
	25.93	

Schedules forming part of Profit & Loss Account for the year ended on 31st March 2022

	As at 31 st March, 2022	As at 31 st March, 2021
	12,373.17 24.87 12,398.04	
	432.86 2.12 1.91 0.25 437.13 3.28 24.45 0.19 18.40 - - 3.42 - 7.79 0.21 494.87	
	169.00 779.08 948.08 172.99 775.10 148.44 396.92 545.36 146.60 398.76 1,173.86	
	2,198.08 2,198.08	
	45.41 182.22 426.78 14.78 44.64 117.89 272.31 5.87 (0.76) (64.33) (154.47) (8.90) (228.47)	

	As at 31 st March, 2022	As at 31 st March, 2021
	3,297.02	
	325.19	
	26.89	
	3,649.09	

	34.80	
	8.64	
	43.44	

	189.86	
	189.86	

	61.41	
	62.80	
	-	
	174.12	
	251.27	
	337.98	
	1,410.63	
	18.53	
	120.70	
	11.25	
	70.66	
	27.10	
	66.45	
	1.40	
	28.46	
	129.14	
	108.06	
	2,879.94	

	7.25	
	2.50	
	1.50	
	11.25	

	0.04	7.89
	99.23	
	4.27	
	3.23	
	0.94	
	0.02	
	0.32	108.06
		115.95

	As at 31 st March, 2022	As at 31 st March, 2021
	735.00 29.58 (7.21) 757.37	
	2,987.09 25.17 751.79 - 185.47 203.06 734.20 735.00 7.06 (47.19) (40.13) 694.87 23.26	
	6.12 86.82 47.64 (10.55) 130.01	
	2,229.72 45,89,378.00 48.58 10	
	1 3,000 0.31	
	238.85 10.82 24.10 3.12 - 276.89	
	2,102.58 2,102.58	

	As at 31 st March, 2022	As at 31 st March, 2021
	-	
	-	
	-	
	1.00	
	1.00	

Name of the Related Party	Relationship

	As at 31 st March, 2022	As at 31 st March, 2021
	26.63	
	54.72	
	5.23	
	5.27	
	62.85	
	51.00	
	1.85	

	172.56	
	54.11	
	38.49	

	30.00	
--	-------	--

	As at 31 st March, 2022	As at 31 st March, 2021
	1,645.16	
	10.21	
	5.34	
	-	
	-	

Particulars	As at 31 st March, 2022	As at 31 st March, 2021
	70.61 7.29	
	Gratuity 01-Apr-21 31-Mar-22 12 Months	
	6.80% 6.80% 7.00% 17%, 5% and 3% Category-wise Indian Assured Lives Mortality (2006-08) Ultimate	
	7.23% 7.23% 7.00% 17%, 5% and 3% Category-wise Indian Assured Lives Mortality (2006-08) Ultimate	
	605.21 41.15 52.29 0.00 0.00 0.00 0.00 0.00 0.00 (55.73) 0.00 (0.02) (23.31) (23.70) 595.90	

Particulars	As at 31 st March, 2022	As at 31 st March, 2021
	536.22	
	36.46	
	78.93	
	0.00	
	0.00	
	0.00	
	(55.73)	
	0.00	
	0.00	
	0.00	
	0.61	
	596.50	
	(595.90)	
	596.50	
	0.60	
	0.60	
	605.21	
	-536.22	
	68.99	
	0.00	
	41.15	
	-36.46	
	4.69	
	52.29	
	4.69	
	0.00	
	0.00	
	0.00	
	0.00	
	56.98	
	(47.02)	
	(0.61)	
	0.00	
	(47.64)	
	68.99	
	56.98	
	(47.64)	
	0.00	
	0.00	
	0.00	
	(78.93)	
	(0.60)	

Particulars	As at 31 st March, 2022	As at 31 st March, 2021
	0.00	
	0.00	
	0.00	
	0.00	
	0.00	
	0.00	
	596.50	
	0.00	
	0.00	
	0.00	
	596.50	

	0.01	
	113.30	
	0.00	
	0.00	
	595.90	
	0.00	
	49.44	

	595.90	
	(596.50)	
	(0.60)	
	43.08	
	(43.13)	
	-0.04	

	50.04	
	-0.04	
	0.00	
	50.00	

	38.12	
	46.10	
	35.12	
	46.04	
	54.72	
	239.20	

	595.90	
	(48.71)	
	56.69	
	54.73	
	(47.95)	
	0.78	
	(0.93)	



Particulars	As at 31 st March, 2022			As at 31 st March, 2021		
	Fair Value through other comprehensive Income Amount	Fair Value through Profit and Loss	Amortised Cost	Fair Value through other comprehensive Income Amount	Fair Value through Profit and Loss	Amortised Cost
	766.00	-	30.12			
			1,520.68			
			503.13			
			4,399.18			
			32.25			
			3,593.40			
			93.97			
			581.53			
			711.03			
			849.78			

Particulars	As at 31 st March, 2022	Fair Value Measurement at the end of the reporting period			As at 31 st March, 2021	Fair Value Measurement at the end of the reporting period		
		Level 1	Level 2	Level 3		Level 1	Level 2	Level 3
	766.00	766.00	-	-				
	-	-	-	-				

Movement in the expected credit loss allowance on trade receivables	For the year ended 31 st March 2022	For the year ended 31 st March 2021
	30.08	
	8.37	
	10.88	
	-	
	27.57	

Outstanding for following periods from due date of payment as on 31/3/2022							
Particulars	Not Due	Less than 6 months	6 months to 1 year	1-2 years	2-3 years	More than 3 years	Total

Outstanding for following periods from due date of payment as on 31/3/2021							
Particulars	Not Due	Less than 6 months	6 months to 1 year	1-2 years	2-3 years	More than 3 years	Total

Particulars	Less than 1 year	1-3 years	More than 3 years	As at 31 st March 2022

Particulars	Less than 1 year	1-3 years	More than 3 years	As at 31 st March 2021

Particulars	US \$ (converted in ₹)	Euro (converted in ₹)	Total as at 31 st March 2022 (in ₹)	US \$ (converted in ₹)	Euro (converted in ₹)	Total as at 31 st March 2021 (in ₹)
	405.87	286.16	692.03			
	53.09	54.20	107.28			
	23.78	70.50	94.28			
	345.20	92.25	437.45			

	As at 31 st March 2022 Amount (₹)	As at 31 st March 2021 Amount (₹)
	30.12	
	766.00	

Green Initiatives

Form Name	Purpose and web-link of the forms

Notes

Financial Highlights

(₹ in Lac)

Description	2021-22 (IND-AS)	2020-21 (IND-AS)	2019-20 (IND-AS)	2018-19 (IND-AS)	2017-18 (IND-AS)	2016-17 (IND-AS)	2015-16	2014-15	2013-14	2012-13
PROFIT & LOSS ACCOUNT										
Revenue from operations	12,398.04	109,29.42	11,889.09	12,264.43	11,467.42	10,330.60	9,429.95	8,634.02	7,737.97	7,043.03
Other Income	494.87	430.85	421.83	340.97	339.40	295.52	337.77	226.48	163.62	141.47
Gross Revenues /Income	12,892.91	11,360.27	12,310.92	12,605.40	11,806.82	10,626.12	9,767.72	8,860.50	7,901.59	7,184.50
Profit before depreciation, interest and tax (PBDIT)	3,220.39	2,415.08	2,396.27	2,837.23	2,718.13	2,267.60	1,919.81	1,735.55	1,314.69	1,124.47
Profit before Tax	2,987.09	2,164.17	2,113.78	2,663.34	2,526.89	2,047.89	1,682.83	1,434.00	1,032.88	882.38
Profit after Tax (PAT)	2,229.72	1,650.24	1,486.96	1,79.78	1,721.22	1,350.77	1,077.90	964.92	750.63	621.53
Dividend	550.73	468.12	1012.49	331.97	618.97	-	402.90	352.53	275.58	226.94
Dividend (₹) on 10/- paid-up	12.00	10.20	8.10	10.20	9.00	8.10	7.20	6.30	5.10	4.20
BALANCE SHEET										
Share Capital	458.94	458.94	458.94	458.94	458.94	464.93	464.93	464.93	464.93	464.93
Reserves & Surplus	11,279.31	9,387.69	7,541.49	7,287.61	5,667.09	4,978.74	3,553.94	2,878.94	2,265.73	1,800.17
Net worth	11,738.25	9,846.63	8,000.43	7,746.55	6,126.03	5,443.67	4,018.87	3,343.87	2,730.66	2,265.10
Long Term Loans / Provision	343.11	390.44	426.46	274.38	302.39	316.86	312.51	269.92	261.23	252.73
Capital Employed (A+B+E):	6,623.46	7,292.30	8,158.79	7,763.41	6,242.05	5,621.67	4,333.21	3,625.57	3,595.15	3,113.70
Net fixed assets (A)	1,139.87	1,055.01	1,172.79	959.18	956.83	1,062.64	1,210.65	1,160.45	1,357.05	1,422.64
Capital Work in Progress (B)	21.17	37.76	11.81	99.00	0.00	0.00	0.00	0.00	0.00	0.00
Current Assets (C)	7,590.41	7,992.14	8,954.27	8,966.79	6,592.16	6,388.60	4,530.93	4,860.35	3,818.06	3,441.36
Current Liabilities (D)	2,127.98	1,792.61	1,980.08	2,261.56	1,306.94	1,829.57	1,408.37	2,395.23	1,579.96	1,750.30
Net Current Assets (C-D)= (E)	5,462.43	6,199.53	6,974.19	6,705.23	5,285.22	4,559.03	3,122.56	2,465.12	2,238.10	1,691.06
Investments	796.12	650.07	249.67	185.61	162.82	138.64	61.32	31.21	31.21	31.21
RATIO & STATISTICS										
PBDIT as % of gross revenue	24.98	21.26	19.46	22.51	23.02	21.34	20.36	20.10	16.99	15.97
PAT as % of gross revenue	17.29	14.53	12.08	15.70	14.58	12.71	11.43	11.18	9.70	8.82
ROCE %	33.66	22.75	18.25	25.50	27.57	24.03	24.88	26.61	20.88	19.96
RONW %	19.00	16.76	18.59	25.56	28.10	24.81	26.82	28.86	27.49	27.44
Current Ratio	3.57	4.46	4.52	3.96	5.04	3.49	3.22	2.03	2.42	1.97
Earning per share (₹)	48.58	35.96	32.40	43.14	37.50	29.05	23.18	20.75	16.15	13.37
Book Value per equity share (₹)	160.40	158.90	177.78	168.79	133.49	117.09	86.44	71.92	58.73	48.72

Follow us on

(1) Facebook: <https://www.facebook.com/zixapainrelief>

(2) Instagram: <https://www.instagram.com/zixapainrelief/>

(3) Twitter: <https://twitter.com/zixapainrelief>

(4) YouTube Channel: <https://www.youtube.com/channel/UCip8o7vHulKBXFnQWYJvCA>



BOOK POST

Jenburkt Pharmaceuticals Limited

Nirmala Apartments, 93, Jayprakash Road,
Andheri (West), Mumbai-400058.

Tel.: +91-22-66943121, Fax: +91-22-66943127,
Email: investor@jenburkt.com • Web: www.jenburkt.com

